6,811 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by OneAscent Wealth Management LLC

OneAscent Wealth Management LLC purchased a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,811 shares of the company’s stock, valued at approximately $244,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Captrust Financial Advisors lifted its holdings in Guardant Health by 33.2% during the second quarter. Captrust Financial Advisors now owns 1,087 shares of the company’s stock valued at $44,000 after purchasing an additional 271 shares in the last quarter. Ameritas Advisory Services LLC purchased a new position in Guardant Health during the first quarter valued at $27,000. Nelson Van Denburg & Campbell Wealth Management Group LLC purchased a new position in Guardant Health during the first quarter valued at $89,000. Acadian Asset Management LLC purchased a new position in Guardant Health during the first quarter valued at $37,000. Finally, Manchester Capital Management LLC purchased a new position in Guardant Health during the first quarter valued at $51,000. 92.65% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

GH has been the topic of several research reports. William Blair reissued an “outperform” rating on shares of Guardant Health in a research note on Friday, September 8th. Piper Sandler raised their price target on shares of Guardant Health from $30.00 to $40.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 8th. Morgan Stanley cut their price objective on shares of Guardant Health from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 7th. Finally, Citigroup raised their price objective on shares of Guardant Health from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, August 4th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $56.87.

Insider Transactions at Guardant Health

In other news, insider Kumud Kalia sold 2,125 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $32.59, for a total transaction of $69,253.75. Following the completion of the sale, the insider now owns 7,813 shares in the company, valued at approximately $254,625.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 6.20% of the company’s stock.

Guardant Health Stock Down 4.0 %

Guardant Health stock traded down $1.23 during trading on Friday, reaching $29.53. The stock had a trading volume of 2,356,838 shares, compared to its average volume of 1,920,657. Guardant Health, Inc. has a 52-week low of $20.67 and a 52-week high of $62.75. The business has a 50 day moving average price of $36.60 and a 200 day moving average price of $31.42. The company has a quick ratio of 6.65, a current ratio of 6.96 and a debt-to-equity ratio of 3.89. The stock has a market cap of $3.48 billion, a PE ratio of -6.01 and a beta of 0.87.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.58. Guardant Health had a negative net margin of 99.62% and a negative return on equity of 427.89%. The company had revenue of $137.15 million during the quarter, compared to the consensus estimate of $129.44 million. During the same quarter in the previous year, the firm earned ($2.25) earnings per share. The firm’s quarterly revenue was up 25.7% on a year-over-year basis. On average, analysts predict that Guardant Health, Inc. will post -3.9 EPS for the current year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.